Da wird an einem Tag plötzlich die zehnfache Menge an Aktien unter hohen Kursverlusten umgesetzt und jeder beteuert nicht zu wisen was da los ist.
Und heute, zwei Wochen später, kommt dann die entsprechende Meldung *ggg* - vorbörslich halbiert sich der Kurs mal eben.
GTC Execs Don't Know Reason for Stock Drop
Wednesday February 8, 4:13 pm ET
GTC Biotherapeutics Execs Say They Know of No Reason for 17 Percent Stock Price Drop on Wednesday
NEW YORK (AP) -- Shares of GTC Biotherapeutics Inc. were down nearly 17 percent Wednesday, but the Framingham, Mass. biotechnology company said they knew of no reason for the stock to drop.
The company said in an afternoon release, "it is unaware of any reason for the unusual trading activity today in its common stock."
ADVERTISEMENT
The company's shares recovered slightly after the statement was issued, but remained down 29 cents, or 14.8 percent, at $1.67 on the Nasdaq, on volume of 9.6 million shares, more than 21 times average daily volume. Earlier in the session, shares changed hands as low as $1.10.
GTC said it did not expect to have any announcement for several weeks regarding its submission of its lead product, ATryn, to the European Medicines Agency. The product is a plasma protein designed to treat a hereditary deficiency. The European submission is the company's first attempt to get a product approved.
ATryn has also been given the go ahead for further study in the U.S. by the Food and Drug Administration.
GTC says European committee negative on Atryn
Thu Feb 23, 2006 7:54 AM ET
CHICAGO, Feb 23 (Reuters) - GTC Biotherapeutics Inc. (GTCB.O: Quote, Profile, Research) on Thursday said it has been told that the Committee for Medicinal Products for Human Use of the European Medicines Agency will issue a negative opinion on its market authorization application for its drug Atryn.
Atryn is GTC's recombinant form of human antithrombin, a protein in human plasma that has anticoagulant and anti-inflammatory properties.
§GTC says European committee negative on Atryn
GTC said the committee, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval. In addition, the committee expressed concerns about sufficient immunologic data.
Framingham, Massachusetts-based GTC said it intends to take advantage of the appeal process to request a re-examination of its submission.
Never argue with an idiot -- they drag you down to their level, then beat you with experience.
Und heute, zwei Wochen später, kommt dann die entsprechende Meldung *ggg* - vorbörslich halbiert sich der Kurs mal eben.
GTC Execs Don't Know Reason for Stock Drop
Wednesday February 8, 4:13 pm ET
GTC Biotherapeutics Execs Say They Know of No Reason for 17 Percent Stock Price Drop on Wednesday
NEW YORK (AP) -- Shares of GTC Biotherapeutics Inc. were down nearly 17 percent Wednesday, but the Framingham, Mass. biotechnology company said they knew of no reason for the stock to drop.
The company said in an afternoon release, "it is unaware of any reason for the unusual trading activity today in its common stock."
ADVERTISEMENT
The company's shares recovered slightly after the statement was issued, but remained down 29 cents, or 14.8 percent, at $1.67 on the Nasdaq, on volume of 9.6 million shares, more than 21 times average daily volume. Earlier in the session, shares changed hands as low as $1.10.
GTC said it did not expect to have any announcement for several weeks regarding its submission of its lead product, ATryn, to the European Medicines Agency. The product is a plasma protein designed to treat a hereditary deficiency. The European submission is the company's first attempt to get a product approved.
ATryn has also been given the go ahead for further study in the U.S. by the Food and Drug Administration.
GTC says European committee negative on Atryn
Thu Feb 23, 2006 7:54 AM ET
CHICAGO, Feb 23 (Reuters) - GTC Biotherapeutics Inc. (GTCB.O: Quote, Profile, Research) on Thursday said it has been told that the Committee for Medicinal Products for Human Use of the European Medicines Agency will issue a negative opinion on its market authorization application for its drug Atryn.
Atryn is GTC's recombinant form of human antithrombin, a protein in human plasma that has anticoagulant and anti-inflammatory properties.
§GTC says European committee negative on Atryn
GTC said the committee, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval. In addition, the committee expressed concerns about sufficient immunologic data.
Framingham, Massachusetts-based GTC said it intends to take advantage of the appeal process to request a re-examination of its submission.
Never argue with an idiot -- they drag you down to their level, then beat you with experience.
